Janus Henderson Group
TRIB

Janus Henderson Group’s Trinity Biotech TRIB Stock Holding History

Janus Henderson Group’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4,871
Closed -$884K – 1462
2019
Q3 		$884K Sell
4,871
-3,204
-40% -$835K ﹤0.01% 1232
2019
Q2 		$2.24M Hold
8,075
– – ﹤0.01% 1137
2019
Q1 		$3.45M Sell
8,075
-1,187
-13% -$489K ﹤0.01% 1054
2018
Q4 		$3.18M Sell
9,262
-49
-0.5% -$22.7K ﹤0.01% 1039
2018
Q3 		$5.59M Sell
9,311
-46
-0.5% -$30K ﹤0.01% 1017
2018
Q2 		$7.02M Sell
9,357
-16
-0.2% -$11.5K ﹤0.01% 970
2018
Q1 		$7.24M Sell
9,373
-56
-0.6% -$45.8K ﹤0.01% 951
2017
Q4 		$7.23M Hold
9,429
– – ﹤0.01% 924
2017
Q3 		$7.93M Hold
9,429
– – 0.01% 901
2017
Q2 		$8.49M Buy
+9,429
New +$8.01M 0.01% 903

Other funds holding TRIB

SCM
Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return
FM
Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ARM
Adirondack Research & Management Guilderland, New York $82.2M AUM 63.78% 1-Year Est. Return

Janus Henderson Group's TRIB Position: Q4 2019 in Review

Janus Henderson Group sold out of Trinity Biotech (TRIB) in Q4 2019, closing a stake of 4,871 shares — an estimated $884K sold.

Janus Henderson Group first reported a position in TRIB in Q2 2017 and held it in 10 quarters. The position peaked at $8.49M in Q2 2017. 25 funds tracked by Wall St. Rank hold TRIB as of Q4 2019.

  • Janus Henderson Group reported no remaining Trinity Biotech position as of Q4 2019 after selling out during the quarter.
  • Janus Henderson Group sold 4,871 Trinity Biotech shares in Q4 2019, an estimated $884K.
  • Janus Henderson Group first reported a position in Trinity Biotech in Q2 2017 and held it in 10 quarters.
  • Janus Henderson Group's Trinity Biotech position peaked at $8.49M in Q2 2017.
  • 25 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2019.

Based on Janus Henderson Group's 13F filing for Q4 2019, filed 18 Feb 2020.